tbuckley/cabot-search huggingface dataset:
THU0608 Visualization and Analysis Platform in The Swedish Rheumatology Register for Real-Time Data Feedback
Authors: D. Di Giuseppe, H. Eriksson, A.-C. Elkan, S. Ernestam
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Swedish Rheumatology Quality register (SRQ) started in 1995 and is one of the largest register collecting data on rheumatoid arthritis and other rheumatic diseases in the world. The aim of the register has always been to support health care along with collect data for research. The national coverage is 82.7% in rheumatoid arthritis. However, the extraction of useful real-time data in every day practice have been so far only limited. <h3>Objectives</h3> To design and implement a tool connected to the SRQ that allows users to monitoring their local data and results of care in comparison to national data. <h3>Methods</h3> We designed a Visualization and Analysis Platform (VAP) based on R language, using the web framework of Shiny (© RStudio, Inc.). The platform is based on predefined types of analyses such as flexible tabular presentations, cross-sectional and longitudinal comparisons. A user interface with reactive programming was implemented to control the appearance of interactive graphs and tables, and to explore the changes in outcome measures. <h3>Results</h3> A web-based platform for live visualization of data was developed and linked to the SRQ, a register containing ca. 75,000 patients and 500,000 registered visits, as long as 60,000 prescriptions of biological treatments. The users is able to control the specifics of the data analysis using a flexible interface, and it can visualize the results in a graph as long as in a table, that can easily be download. An explanation of the graph is included, to support the user in the understanding of what is represented. The VAP tool has been used to visualize data on the so called Open Comparison diagrams, 5 quality indicators that have been discussed at national level and that have been used to evaluate performances of care across counties in Sweden. We also applied this tool to the analysis of use of biological treatments in Stockholm (Fig.1). The user is therefore able to visualize how many times a specific biological treatment has been prescribed in his unit and compare it to the national value, as long as select different periods of time of interest and different diagnosis. <h3>Conclusions</h3> The VAP offers a flexible tool for visualization and analysis of real-time SRQ9s data and it is aimed to satisfy the growing request of data by clinicians, patients, researchers, care providers and pharma companies. Moreover, the VAP tool by its nature allows the possibility of fast changes in this structure, following the changes in everyday rheumatology care in real-time. <h3>Disclosure of Interest</h3> None declared
PTH-041 Per Oral Endoscopic Myotomy: First UK Experience
Authors: S Gulati, A Emmanuel, H Inoue, T Wong, J Jafari, B Hayee, A Haji
Journal: Gut (2016)

<h3>Introduction</h3> Per-oral endoscopic myotomy (POEM) has been adopted as a minimally invasive treatment option for achalasia. The first case of POEM was performed at King’s College Hospital in late 2013. Here we present our initial case series with video demonstration of technique. <h3>Methods</h3> Prospective data was collected for consecutive patients undergoing POEM including demographics, procedure technique, the use of Endoluminal Functional Lumen Imaging Probe (EndoFLIP) and adverse events. Follow up data at 3 months and 12–24 months post-POEM including Eckardt scores and lower oesophageal sphincter integrated resting pressure (IRP-4s) were compared with pre-POEM findings. Post-POEM Gastro-oesophageal Reflux Health-Related Quality of Life scale (GORD-HQL) was recorded. Statistical analysis was achieved using Wilcoxon matched-pairs signed rank test. <h3>Results</h3> POEM was performed in 33 patients (12 F, age 49.5±13.25 years). Pre-operative high-resoloution manometry confirmed type II achalasia in all patients. 19 patients had previous treatment (Botulinum n = 8, Pneumatic dilatation n = 10, Heller myotomy n = 5, POEM n = 1, &gt;1 treatment n = 2). Median pre-POEM Eckardt Score 8, range 3–12. Median gastric and oesophageal myotomy was 3 cm (range 2–4) and 12 cm (range 5–16) respectively with a selective circular myotomy in all cases and a posterior approach in n = 5. There was significant reduction in post-operative Eckardt score at 3 months Median 0, range 0–6 (p &lt; 0.0001) and IRP-4s (p = 0.0078, figs. 1 and 2). Sustained improvement in Eckardt score was observed at 12–24 months post-POEM (p = 0.0005). One patient required revision of POEM at 6 months. EndoFLIP Intra-operative EndoFLIP measurements before and after myotomy have been implemented to aid confirmation of adequate myotomy (Figure 3). Adverse Events One patient underwent single clip displacement and was replaced at gastroscopy day 1 post POEM. There were no cases of perforation, infection or major bleeding. Gastro-oesophageal reflux Post-POEM GORD-HQL score was collected in 26 patients with a median score of 2.5, range 0–31. Two cases of reflux (positive 24 hr pH at 3 months) were identified and successfully managed with maintenance proton pump inhibitor. <h3>Conclusion</h3> POEM was performed successfully in 33 patients in whom 57.5% had prior endoscopic or surgical treatment representing a potentially more challenging patient population. This study is in line with international consortia and ASGE findings<sup>1</sup> that POEM is a safe and efficacious procedure for the treatment of achalasia for both short term and sustained symptomatic benefit. <h3>Reference</h3> 1 Stavropoulos S, Desilets D, Fuchs KH <i>et al</i>; Per-oral endoscopic myotomy white paper summary; <i>Gastrointestinal Endoscopy</i>. 2014;<b>1</b>:1–15. <h3>Disclosure of Interest</h3> None Declared
AB0463 Clinical Characteristics of Elderly Patients with Primary Sjögren's Syndrome
Authors: K. Nakanishi, M. Kinjo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Sjögren9s syndrome is a common autoimmune disorder with the majority of cases occurring in midlife. Although the clinical presentation of primary Sjögren9s syndrome (pSS) is known to differ by age, clinical characteristics of elderly patients with pSS have not been well described. <h3>Objectives</h3> To identify clinical characteristics of patients with pSS based on age group. <h3>Methods</h3> We retrospectively identified all patients with biopsy-proven lymphocytic sialadenitis and/or positive anti-SSA/Ro antibody who were treated at a tertiary medical center in Japan between 2005 and 2015. Data were collected on their clinical and laboratory features. Definite pSS was defined by the fulfilled American-European Consensus (AEC) criteria for pSS and probable pSS was determined by any 3 of the 6 AEC criteria without other collagen diseases. Clinical and laboratory characteristics of patients aged 60 years or older were compared with those of their younger counterparts. <h3>Results</h3> We identified 402 Japanese patients with biopsy-proven lymphocytic sialadenitis and/or positive anti-SSA/Ro antibody. 147 (37%) had pSS, 36 (9%) were undifferentiated, and 219 (54%) had at least one or more antinuclear antibody-associated collagen diseases. The median age of the pSS patients was 52 years (range 17–89); 41% (60 patients) were aged 60 years or older, and 91% were female (Table). Compared to the younger age group, the older patients were more likely to have dry mouth, primary biliary cirrhosis, lymphoma and thrombocytopenia. The younger patients had a greater likelihood of arthritis and a photosensitive rash (p&lt;0.05). <h3>Conclusions</h3> Clinical characteristics of pSS may differ between younger and elderly patients. In elderly patients with pSS, careful evaluation for coexisting primary biliary cirrhosis or lymphoma is recommended. <h3>References</h3> Chudwin DS, Daniels TE, Wara DW, et al: Spectrum of Sjögren9s syndrome in children. J Pediatr 98:213, 1981. Vitali C, Bombardiere S, Jonsson R, et al: Classification criteria for Sjögren9s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554, 2002. <h3>Acknowledgement</h3> We thank Dr. Thomas Lynn Hurt and Kimitoshi Yamaguchi (database). <h3>Disclosure of Interest</h3> None declared
Integrative Genomic Approach Identifies Deregulated MicroRNAs in Human Myeloma Cell Lines.
Authors: Marta Lionetti, Luca Agnelli, Laura Mosca, Katia Todoerti, Domenica Ronchetti, Sonia Fabris, Adrian Andronache, Donata Verdelli, Paola Ponzo, Giorgio Lambertenghi Deliliers, Antonino Neri
Journal: Blood (2008)
Prognostic Significance of NOTCH1 and FBXW7 Mutations in Childhood T-Cell Acute Lymphoblastic Leukemia (T-ALL): Results From the EORTC Children Leukemia Group.
Authors: Emmanuelle Clappier, Sandra Collette, Nathalie Grardel, Sandrine Girard, Lydia Suarez, Ghislaine Brunie, Sophie Kaltenbach, Karima Yakouben, Françoise Mazingue, Alain Robert, Patrick Boutard, Dominique Plantaz, Pierre-Simon Rohrlich, Claude Preudhomme, Frank Speleman, Jacques Otten, Nicole Dastugue, Stefan Suciu, Yves Benoit, Yves Bertrand, Hélène Cavé
Journal: Blood (2009)
AB1000 Evaluation of The Presence and Frequency of Neuropathic Pain Component in Myofascial Pain Syndrome
Authors: E. Tas, H. Genc, B. Nacir, A. Karagoz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Neuropathic Pain Component in Myofascial Pain Syndrome is very imoprtant in the grups of aged between 20–50 years which is neck or upper back region. It was evalueyted by using specific diagnostic crtiteria, visual analog scale (VAS) and Neck Pain and Disability Index (NPDI) <h3>Objectives</h3> The aim of this study was to determine the presence and incidence of neuropathic pain in myofascial pain syndrome (MPS) and to detect factors that may be related to neuropathic pain <h3>Methods</h3> 112 patients with MPS in their neck or upper back region (aged between 20–50 years) and 62 age, gender and body mass index matched, healthy controls were included in the study. The existence of MPS was evaluated using specific diagnostic crtiteria. Pain assessment was made by visual analog scale (VAS). Neck Pain and Disability Index (NPDI) was used for the evaluation of the disability depends on neck and upper back pain. The existence of neuropathic pain component in both trigger point and referred pain regions was assessed with Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), painDETECT and Douleur Neuropathique 4 (DN4) questionnaires. <h3>Results</h3> Mean ages of the patients with MPS was 33.4±8.0 years and controls was 33.5±8.4 years (p&gt;0.05). The mean VAS score for pain and the mean NPDI values were significantly higher in the patients group (5.9±1.0 and 35.7±28.3, respectively, p&lt;0.001). Neuropathic pain component was identified at both trigger points and referred pain areas in the patients group. Neuropathic component in the trigger point area was detected in 19 of 112 patients (17%) using DN4, in 4 patients (3.6%) using LANSS and in 2 patients (1.8%) using painDETECT scales. On the other hand; DN4, LANSS and painDETECT scales showed positive results for neuropathic component at 33 (% 29.5), 14 (% 12.5) and 12 (%10.7) of 112 patients in referred pain areas, respectively. Significant correlations were found between the higher values of NPDI and VAS with DN4, LANSS and painDETECT values in patiens with MPS. <h3>Conclusions</h3> In this study, the existence of neuropathic component was determined in both trigger point and referred pain regions of patients with MPS. Neuropathic component was more prominent in the referred pain area. Central pain mechanisms may be responsible for this result. Further studies with more patients are needed to confirm our results. We think that, it is important to consider neuropathic component in the treatment of MPS. <h3>Disclosure of Interest</h3> None declared
Increased Interleukin-17 Proportion in Helper T Cell (Th17) in Patients Post Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Andrzej Lange, Dorota Dlubek, Mariola Sedzimirska, Daria Drabczak-Skrzypek, Emilia Jaskula, Janusz Lange
Journal: Blood (2007)
Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials
Authors: Joseph M. Connors, Randy D. Gascoyne, Paul Hoskins, James Morris, Tom Pickles, Laurie Sehn, Tamara Shenkier, Richard Klasa, Nicholas Voss, Kerry Joanne Savage
Journal: Blood (2010)
Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience
Authors: Neha Mehta-Shah, Joanne Chou, Molly Maloy, Zhigang Zhang, Alison J. Moskowitz, Craig H Moskowitz, Juliet N. Barker, Sergio Giralt, Miguel-Angel Perales, Steven M Horwitz, Craig S. Sauter, Parastoo B. Dahi
Journal: Blood (2015)
Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study
Authors: Rong Wang, Amer M. Zeidan, Pamela R Soulos, James B. Yu, Amy J. Davidoff, Steven D. Gore, Cary P. Gross, Xiaomei Ma
Journal: Blood (2015)
Comparison of the Antithrombotic Effectiveness of the Direct Thrombin Inhibitor, Dabigatran Etexilate, and Two Factor Xa Inhibitors in an A-V Shunt Model of Thrombosis in Rabbits.
Authors: Joanne van Ryn, Norbert Hauel, Henning Priepke, Kai Gerlach, Annette Schuler-Metz, Wolfgang Wienen
Journal: Blood (2007)
PWE-004 Diagnostic Accuracy of Magnetic Resonance Enterography in Detecting Small Bowel Crohn’s Disease – Relationships with Faecal Calprotectin
Authors: A Nelson, P Oka, D Petty, C Wilkinson, P Kant
Journal: Gut (2016)

<h3>Introduction</h3> Around one third of patients with Crohn’s disease (CD) have isolated small bowel involvement at diagnosis. Magnetic resonance enterography (MRE) is a recognised tool for identifying small bowel disease. Faecal calprotectin (FCp) is a marker to help differentiate functional from organic gastrointestinal symptoms and is typically elevated in CD. This study aims to determine the diagnostic accuracy of MRE in patients with symptoms suspicious for CD and assess the relationship between FCp and presence of small bowel disease on MRE. <h3>Methods</h3> Patients with suspicion for CD who underwent MRE over a 23 month period (Jan 2013 to Nov 2014) were identified using a local database. All study patients had undergone a normal colonoscopy to exclude Crohn’s colitis. MRE reports were reviewed for evidence of small bowel abnormalities, and whether these were likely to represent CD. FCp levels (μg/g) from 3 months preceding MRE were recorded. Casenote review revealed outcome and patient disposition at 1 year post-MRE. <h3>Results</h3> In total 73 patients underwent MRE (mean age 37.5; range 13–77; 46:27 female:male). 3 had MRE findings radiologically diagnostic for CD, their FCp ranged from 389 to 600. 19/73 patients had MRE features of non specific ileitis with corresponding median FCp level of 222 (inter-quartile range [IQR] 71–600). At 1 year a further of 3 of these 19 patients (FCp range 294–600) were positively diagnosed as CD. Of the remaining 16 with non specific ileitis on MRE, none had CD at 1 year. In this sub-group the median FCp was 139 (45–517), 5 had a normal capsule endoscopy, 12 had functional pain, 3 had infectious ileitis, and 1 was lost to follow-up. The majority of patients however (51/73 [69.9%]) had normal MRE with a median FCp of 142 (83–416) and none had CD at 1 year. Median differences in the FCp value between those with normal and abnormal MRE were apparent but not statistically significant (p = 0.42). Overall sensitivity of MRE in diagnosing small bowel involvement is high at 100% as is a negative predictive value of 100% although we acknowledge the small sample size. Within the group reported as indeterminate Ileitis only 3/19 were subsequently diagnosed with Crohn’s disease. <h3>Conclusion</h3> MRE excels in excluding small bowel CD in suspected patients and is reliable when positively diagnosing Crohn’s. In early Crohn’s disease there is uncertainty in differentiating the radiological appearances with other causes of ileitis. These data support the development of an appropriate threshold for abnormal FCp as a screening tool to improve MRE accuracy. This could reduce the number of unnecessary MRE examinations without missing any cases of small bowel CD. <h3>Disclosure of Interest</h3> None Declared
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma
Authors: Barbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, Alexander Egle, Peter Neumeister, Daniela Voskova, Marius Erik Mayerhoefer, Ingrid Simonitsch-Klupp, Thomas Melchardt, Richard Greil, Markus Raderer
Journal: Blood (2016)
Increased C-Jun and Reduced GATA2 Expression Promotes Aberrant Monocytic Differentiation and Expansion Induced by Activating PTPN11 Mutants
Authors: Zhenyun Yang, Takako Kondo, Cara s Voorhorst, Sarah C Nabinger, Leila Ndong, Fuqin Yin, Edward m Chan, Oliver Wurstlin, Christian Kratz, Charlotte Marie Niemeyer, Christian Flotho, Eri Hashino, Rebecca Chan
Journal: Blood (2008)
SAT0523 Efficacy of Local Autologous Platelet Rich Plasma Injection Compared To Local Corticosteroid in Treatment of Plantar Fasciitis; An Ultrasonographic Evaluation
Authors: N.A. Sherpy, M.A.H. Hammad, E.H. Hagrass, H. Samir, S. Abu Elmaaty, M. Mortada
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Plantar fasciitis (PF) is the most common cause of heel pain. Corticosteroid injections are used for cases of PF refractory to conservative treatment. Platelet-rich plasma (PRP) has been gaining popularity as a treatment for PF pain. <h3>Objectives</h3> The aim of this study was to compare between local autologous PRP injections and local steroid injections both clinically and sonographically within 3-months regarding its effect on pain, function, thickness, and echogenecity of the plantar fascia and also regarding its safety. <h3>Methods</h3> This study was carried out on 50 patients with chronic PF, attending the Rheumatology and Rehabilitation outpatient clinic in Zagazig University Hospitals. Patients were divided into two groups: Steroid group (n=25) and PRP group (n=25). Pre-injection all patients of our study were subjected to full history taking, thorough physical examination, visual analogue scale (VAS: 0–100), Foot Health Status Questionnaire (FHSQ) which included Short Form 36 (SF36), complete blood count (CBC) to exclude anemia and thrombocytopenia, plain x- ray to detect calcaneal spur, and ultrasonography. Patients were reassessed by VAS, FHSQ, and ultrasonography at 1.5 months &amp; 3 months postinjection. The clinical evaluator and sonographer were blinded to the type of injection. <h3>Results</h3> We found that at 1.5 months post injection, there was more improvement in the PRP group than the steroid group both clinically and ultrasonographically (p=0.008, p&lt;0.01). Also, although at 3 months no great difference was found between the two groups (p&gt;0.05), PRP patients continued to improve from 1.5 months to 3 months (p=0.000, p&lt;0.01). None of our patients of either groups experienced any complications from injection at the end of the follow-up period. No post-injection foot deformities nor infection were noted (P&gt;0.05). <h3>Conclusions</h3> We suggest that the PRP injection is a new, readily available and safe choice of therapy for PF and is not inferior to steroid injection in short term follow up. To our best knowledge this is the first study to compare steroids and PRP by ultrasonography. <h3>Disclosure of Interest</h3> None declared
SP0055 Experiences from Young Representative of Paediatric Rheumatology European Society
Authors: E. Smith
Journal: Annals of the Rheumatic Diseases (2016)

The Paediatric Rheumatology European Society (PRES) is a European scientific society for healthcare professionals in the field of paediatric rheumatology. The societies missions are to promote knowledge of paediatric rheumatic diseases, stimulate research in this field, disseminate knowledge through scientific meetings and publications, provide guidelines and standards for good clinical practice. Importantly PRES provides guidelines and standards for the training of doctors and allied health professionals in the practice of paediatric rheumatology. As the young/trainee representative on the PRES council I am involved in representing the views of trainees at council meetings. PRES holds a scientific congress each year which is preceded by an annual Young Investigators Meeting (YIM), which I organize along with a local trainee(s). This is a very popular meeting which is increasing in size and currently brings together approximately 150 young investigators (clinicians and scientists) from across Europe but also America, Australia, India, Africa. It is a good opportunity for young investigators to have their first international presentation and network with senior faculty to discuss and develop research ideas. As the trainee representative I am also involved in organising and promoting PRES funded training courses and gaining opinion from trainees about the type or course they would like. PRES plans to run summer/winter schools on certain conditions in the near future. I have recently assisted the PRES Education and Training Committee in updating the European Paediatric Rheumatology syllabus which will be launched in summer 2016. <h3>Disclosure of Interest</h3> None declared
AB0599 Interleukin-35 in Idiopathic Inflammatory Myopathies
Authors: H. Mann, O. Krystufkova, H. Hulejova, J. Zamecnik, J. Hacek, M. Filkova, J. Vencovsky, L. Senolt
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Interleukin-35 (IL-35) is a newly described heterodimeric cytokine that belongs to the IL-12 family and consists of p35 (IL-12a) and EBI3 (IL-27b) subunits. IL-35 exerts immunomodulatory activities in several autoimmune inflammatory diseases. <h3>Objectives</h3> The aim of this study was to assess IL-35 expression in muscle tissue of patients with idiopathic inflammatory myopathies (IIM) and to compare serum levels of IL-35 in patients with IIM to healthy controls and asses potential association with activity of IIM. <h3>Methods</h3> The expression of IL-35 was studied in a series of 19 muscle biopsy samples of idiopathic inflammatory myopathies (9 dermatomyositis, 10 polymyositis) and 10 non-inflammatory control muscle biopsies from patients with myasthenia gravis.Serum levels of IL-35 were measured in 23 PM, 28 DM and 15 cancer associated myositis patients as well as in 40 healthy controls.Disease activity was evaluated by the Myositis Disease Activity Assessment Tool (MYOACT) and by serum muscle enzymes. <h3>Results</h3> Both IL-35 subunits were found in immune cells of the inflammatory infiltrates in IIM muscle biopsies, no immunoreactivity was observed in muscle tissue of control patients.IL-35 serum levels were increased in all IIM patients compared to healthy controls (p&lt;0.001). There were no differences in IL-35 serum levels between myositis subgroups. Serum IL-35 levels correlated with the overall MYOACT score, with extramuscular and muscle domains of MYOACT, with physician9s global activity assessment and lactate dehydrogenase levels. <h3>Conclusions</h3> IL-35 subunits are overexpressed in inflammatory infiltrates in muscle tissue of IIM patients and elevated circulating IL-35 levels correlate with several disease activity parameters. These data suggest potential role of IL-35 in the pathogenesis of inflammatory myopathies. <h3>Acknowledgement</h3> Supported by MHCR support for conceptual development of a research organization (023728) and BTCure (115142–2). <h3>Disclosure of Interest</h3> None declared